Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific

This article was originally published in The Gray Sheet

Executive Summary

Purchase of German stent technology R&D firm Inflow Dynamics adds iridium oxide passive stent coating technology, which "may offer an attractive alternative for the segment of the international market that does not convert to a drug-eluting stent," the firm says. Clinical trials are ongoing. Announced Dec. 5, the deal also covers roughly 30 patents related to stent designs and coatings. Separately, Boston Scientific completes its purchase of neurovascular device maker Smart Therapeutics Dec. 3 (1"The Gray Sheet" Dec. 17, 2001, p. 23). Boston Scientific also is debuting its Maverick2 Monorail and Quantum Maverickcoronary balloon dilatation catheters in the U.S. The firm highlights the versatility and "pushability" of the low-profile Maverick2 and the Quantum Maverick's deliverable dilation force...

You may also be interested in...

Boston Scientific Inks Smart Therapeutics Deal, Closes On Radiotherapeutics

Boston Scientific plans to combine its GDC aneurysm coils with Smart Therapeutics, Inc.'s development-phase intracranial stent system to better treat intracranial aneurysmal disease under a definitive acquisition agreement, announced Dec. 13

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts